Tilray Brands, Inc. TLRY PHARMA
Company Overview
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Shock Top, Montauk Brewing, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point, Alpine, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Cruisies, Atwater Brewery, Hi-ball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
Why Investors Should Care
Revenue has grown at a 42.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.25.
Recent Developments
- May 2026 Revenue of $915.45M (+11.5% YoY); net profit $-121.40M.
- Trailing 12 Months Year-on-year growth — revenue +25.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.88% |
| 1 Year: | 25.50% |
Stock Price Performance
| 1 Year: | -65.60% |
| 6 Months: | -41.50% |
| 3 Months: | -14.51% |
| 1 Month: | -5.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 42.9% over 5 years.
CONS
- Trading 79.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TLRY Tilray Brands, Inc. PHARMA | 4.30 | -3.94 | $603.82M | 0.00% | -2.81% | -6.82% | 42.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Aug 2019 | Sep 2019 | Nov 2019 | Dec 2019 | Feb 2020 | Mar 2020 | May 2020 | Jun 2020 | Aug 2020 | Sep 2020 | Nov 2020 | Dec 2020 | Feb 2021 | Mar 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | Aug 2022 | Nov 2022 | Feb 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | May 2025 | Aug 2025 | Nov 2025 | Feb 2026 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 117.49M | - | 129.46M | - | 123.90M | - | - | 168.02M | 155.15M | 151.87M | 153.21M | 144.14M | 145.59M | 176.95M | 193.77M | 188.34M | 200.04M | - | - | 224.53M | 209.50M | 217.51M | 206.73M | 281.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 156.90M | 152.03M | 160.01M | 151.78M | 191.19M |
| Gross Profit | 2.97M | 2.93M | 3.90M | 4.18M | 3.07M | 3.13M | 5.38M | 12.27M | 20.55M | 15.85M | 21.81M | -57.01M | 25.88M | 10.87M | 27.81M | -5.82M | 34.95M | 3.33M | 35.28M | 16.64M | 30.46M | 13.50M | 22.50M | 50.95M | 32.77M | 39.83M | 48.61M | 42.88M | -11.70M | 44.20M | 47.41M | 49.40M | 59.71M | - | - | 67.63M | 57.47M | 57.50M | 54.95M | 90.52M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.30M | 68.34M | 77.51M | 74.82M | 95.03M |
| Operating Income | -2.18M | -2.61M | -3.74M | -10.99M | -20.01M | -22.91M | -28.44M | -32.96M | - | -23.79M | - | -216.62M | - | -71.25M | - | -75.82M | -8.47M | -32.77M | -25.96M | - | -24.05M | -73.31M | - | -69.37M | -55.53M | -18.08M | -21.18M | -51.79M | -1.21B | -34.36M | -41.76M | -82.10M | -36.57M | - | - | -12.66M | -10.87M | -20.01M | -19.87M | -4.51M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.34B | 21.48M | -18.63M | -1.55M | 8.15M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.35M | 6.70M | 5.37M | 4.96M | 12.88M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.39B | -772.00K | -39.96M | -23.26M | -24.07M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -125.14M | -2.29M | 3.55M | 1.97M | 13.86M |
| Net Income | -1.77M | -2.93M | -5.18M | -12.83M | -18.70M | -31.01M | -29.37M | -36.30M | 1.56M | -36.35M | -6.00M | -219.15M | -11.00M | -184.12M | -87.11M | -81.69M | -34.34M | -2.32M | -99.90M | -2.95M | -273.52M | -340.95M | 47.20M | -41.65M | -201.00K | 43.19M | -73.48M | -69.46M | -1.17B | -71.53M | -49.01M | -92.70M | -39.16M | - | - | -1.27B | -322.00K | -44.93M | -26.57M | -49.57M |
| Diluted EPS | - | - | - | - | - | - | - | - | 0.01 | - | -0.03 | - | -0.05 | - | -0.39 | - | -0.09 | - | -0.41 | - | -1.03 | - | 0.18 | -0.08 | 0.00 | 0.09 | -0.13 | -0.11 | -1.90 | -0.10 | -0.07 | -0.12 | -0.04 | - | - | -13.00 | 0.00 | -0.41 | -0.24 | -0.43 |
| R&D Expense | 729.00K | - | 975.00K | 639.00K | 802.00K | - | 1.05M | 1.53M | - | 2.31M | - | - | - | 1.35M | - | 652.00K | 120.00K | 921.00K | 225.00K | - | 127.00K | 1.20M | - | 785.00K | 515.00K | 164.00K | 166.00K | 165.00K | 171.00K | 79.00K | 56.00K | 106.00K | 105.00K | 60.00K | 85.00K | - | 41.00K | 78.00K | 62.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | May 2019 | Dec 2019 | May 2020 | Dec 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.64M | 20.54M | 43.13M | 179.30M | 166.98M | 405.33M | 210.48M | 513.09M | 628.37M | 627.12M | 788.94M | 821.31M | 915.45M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 480.16M | 565.59M | 580.74M | 655.01M |
| Gross Profit | 2.67M | 11.38M | 14.28M | 43.51M | -23.50M | 96.05M | 24.66M | 123.18M | 116.82M | 146.96M | 223.35M | 240.57M | 260.44M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 325.15M | 336.11M | 348.38M | 315.70M |
| Operating Income | -7.05M | -7.50M | -57.84M | -138.93M | -304.14M | -104.01M | -201.12M | -132.17M | -610.40M | -178.19M | -112.76M | -107.81M | -55.26M |
| EBITDA | - | - | - | - | - | - | - | - | - | -1.27B | -72.84M | -2.13B | 9.45M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 46.61M | 49.26M | 41.33M | 29.91M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -1.45B | -249.02M | -2.30B | -88.06M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -7.18M | -26.62M | -121.02M | 17.10M |
| Net Income | -7.88M | -7.81M | -67.72M | -25.04M | -321.17M | -102.54M | -271.07M | -367.42M | -476.80M | -1.45B | -244.98M | -2.19B | -121.40M |
| Diluted EPS | - | - | - | -0.18 | - | -0.47 | - | -1.36 | -0.99 | -23.50 | -3.30 | -24.56 | -1.09 |
| R&D Expense | 1.14M | 3.17M | 5.86M | 1.05M | 9.17M | 1.92M | 4.41M | 830.00K | 1.52M | 682.00K | 635.00K | 284.00K | 361.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | May 2018 | Dec 2018 | May 2019 | Dec 2019 | May 2020 | Dec 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | Dec 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.95M | - | 656.67M | - | 896.33M | 1.74B | 945.95M | 6.03B | - | 4.31B | 4.22B | 2.07B | 2.07B | 2.33B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 773.03M | 677.71M | 688.63M | - | 792.13M |
| Cash & Equivalents | - | - | 2.32M | - | 487.25M | - | 96.79M | 360.65M | 189.70M | 488.47M | - | 206.63M | 228.34M | 221.67M | 221.67M | 225.98M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 200.55M | 252.09M | 270.88M | - | 301.19M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 86.23M | 101.69M | 121.49M | - | 189.17M |
| Total Liabilities | - | - | 58.80M | - | 459.01M | - | 611.06M | 463.00M | 572.05M | 1.56B | - | 977.32M | 778.49M | 584.75M | 584.75M | 733.14M |
| Current Liabilities | - | - | 50.22M | - | 25.94M | - | 92.43M | 119.89M | 181.28M | 401.24M | - | 432.98M | 299.17M | 280.30M | 280.30M | 358.38M |
| Long Term Debt | - | - | 9.43M | - | - | - | - | 94.03M | - | 167.49M | - | 357.93M | 287.94M | 234.92M | - | 199.95M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 590.13M | 387.32M | 328.74M | - | 398.40M |
| Total Equity | 9.90M | 2.53M | -4.85M | 813.72M | 197.65M | 1.23B | 285.27M | 1.25B | 373.90M | 4.46B | - | 3.32B | 3.44B | 1.51B | 1.51B | 1.61B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 65.67M | 83.19M | 106.07M | - | 131.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | May 2019 | Dec 2019 | May 2020 | Dec 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.32M | -6.00M | -46.25M | -42.05M | -258.06M | -100.63M | -129.35M | -44.72M | - | 7.91M | -30.91M | -94.60M | -69.14M |
| Investing Cash Flow | -1.02M | -11.81M | -98.62M | -134.52M | -253.18M | -69.95M | -41.68M | 46.10M | - | -285.11M | 128.35M | -46.72M | -55.80M |
| Financing Cash Flow | 10.92M | 12.23M | 631.00M | 547.18M | 114.70M | 130.61M | 264.85M | 124.31M | - | 70.16M | -75.19M | 133.51M | 130.99M |
| Capital Expenditure | -488.00K | -10.91M | -50.20M | - | -73.74M | - | -44.64M | - | - | -20.80M | -29.25M | -32.92M | -32.99M |
| Free Cash Flow | -3.81M | -16.91M | -96.45M | - | -331.81M | - | -174.00M | - | - | -12.89M | -60.15M | -127.52M | -102.13M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -207.05M | 22.26M | -7.81M | 6.05M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | May 2019 | Dec 2019 | May 2020 | Dec 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 | May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 21.1% | 55.4% | 33.1% | 24.3% | -14.1% | 23.7% | 11.7% | 24.0% | 18.6% | 23.4% | 28.3% | 29.3% | 28.4% |
| Operating Margin % | -55.7% | -36.5% | -134.1% | -77.5% | -182.1% | -25.7% | -95.6% | -25.8% | -97.1% | -28.4% | -14.3% | -13.1% | -6.0% |
| Net Margin % | -62.3% | -38.0% | -157.0% | -14.0% | -192.3% | -25.3% | -128.8% | -71.6% | -75.9% | -231.6% | -31.1% | -266.3% | -13.3% |
| ROE % | -311.8% | 160.9% | -34.3% | -2.0% | -112.6% | -8.2% | -72.5% | -8.2% | - | -43.8% | -7.1% | -144.7% | -7.5% |
| ROCE % | - | -201.2% | -9.2% | - | -37.8% | -6.4% | -26.3% | -2.4% | - | -4.6% | -2.9% | -6.0% | -2.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tidal Investments LLC | 1.83% | 2.50M | $9.97M |
| 2 | Susquehanna International Group, LLP | 0.75% | 1.02M | $4.08M |
| 3 | Morgan Stanley | 0.73% | 995.14K | $3.97M |
| 4 | Citadel Advisors Llc | 0.64% | 868.15K | $3.46M |
| 5 | Point72 Asset Management, L.P. | 0.48% | 648.51K | $2.59M |
| 6 | Mirae Asset Global ETFs Holdings Ltd. | 0.47% | 646.76K | $2.58M |
| 7 | AQR Capital Management, LLC | 0.38% | 512.60K | $2.05M |
| 8 | Blackrock Inc. | 0.34% | 461.66K | $1.84M |
| 9 | UBS Group AG | 0.33% | 454.18K | $1.81M |
| 10 | Lazard Asset Management LLC | 0.29% | 394.71K | $1.57M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLRY
TLRY Stock Extends Green Run: Tilray Funds Lyphe Buyout And Debt Reduction With 1.6M New Shares - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPdTFoUWhfUmxDMm9LemZsN3ZpZ2RoTUp0MGo0UzhNWF83VmcyZENGLVVzR08tbmlING1GSFZtYVR3bEpJNkdrRFpVc1A4ZC1QQkhJWlJhR3J6ZVE5Mmt2RXpMZlFMR0hzVXZfZ1Vna3hsYnhHVmJ6REpkSlBVaTI5aW9ONXdyZVRQOGZRSm…
Why Tilray Brands, Inc. (TLRY) Dipped More Than Broader Market Today - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOVW1wZ0N6SDFqb2RYRlRnRjVpNWttdHJtNk1fY1lFS1ZKN1RLQ1NwRzA1WEJBeWpZLWh6M2RmS3g2emJuQ2VvX2U5dkY0MW1tZ29rdDBxazNaT3ZDYUZtTUswa2dpbHlxNXc0M09UQ3p4YWtVTUlTR0Z6bWZGbnZOWUFXX29UYWVoSkhrVk…
A rugby club will get its own beer from BrewDog: Leicester Tigers - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNelpGMFJQRUF0bGdfa2o5b1lGUThtdTJXb1QzWjE5YVJNVGM5QzJZVjlaWjB3ejJZZHNrVEtVZmMyNnJteEhaWU9Cb0JPdWlEMklJWUFNMXU4NVpuSzBIVlFESTRaLTJKTmZzVWlmaFlXeDlES1hmc204eklUU3JyZThsTGxlakxBSElYbV…
Tilray Brands Inc. stock falls Tuesday, underperforms market - MarketWatch
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOT1lfT0p4SXFiSm12U2JOMGRRaWNXSjhaTDBzLWdzRFBycExCSmxSMEI1aW1uNzVueUZ0SzBrVENBV2Z4ZWp2UlFOOWhGWmxoNDJpMVRoeGJsOUpKZ1EtUUhLNXRGUG5EQ0pjOFJtbnk3MEdJOGFSMFJsV3M2UlhqT2VuZlBrU1VzQTlEUT…
Tilray Jumps 6%, Canopy Growth Climbs 3%, Aurora Cannabis Gains 4%: Here's Why TLRY Is Still Down 47% YTD - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPM2JLbDFldkluSG9BTUxrMWFHNHNuYUszUFlWU0VpOTlBYkp1MU1udVNlQVpVZWI2RzdjZ2t4cEp0dk9iWkJ6RnoybE4tSFZ3cFVkUWJmZjYtWVNlMTVyLWM1Xy1kSk03UTRPMFlmMTJiUmJzYnBpNVpFcFZaWWRCZUdjOXg3OXNqcHJNNk…
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell? - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWDR2QmFhTm5sSHAwQ3VBelJfTUg2b2luUEFWZ3c3WkMyMFF0dlhRTDdGcWtoN0pEZWprbDNDcW9PVktPT2xpd04xbFpPUk9qdUxtNzZjS2Zwa3p4UnNRMmg1aU5mbk1NLVlqcHJsbnd6NHJlb2VaN25EUmZvb1Z3S0pXZTIxMkU1bHc2Z1…
TLRY — Frequently Asked Questions
What is the current share price of Tilray Brands, Inc. (TLRY)?
As of 2026-09-19 21:16 PDT, Tilray Brands, Inc. (TLRY) trades at $4.30 on NasdaqGS. Its 52-week range is $3.88 to $21.00.
What is the market capitalisation of TLRY?
Tilray Brands, Inc. (TLRY) has a market capitalisation of $603.82M on NasdaqGS.
What is the P/E ratio of TLRY?
TLRY trades at a trailing price-to-earnings (P/E) ratio of -3.94. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.32.
What is the return on equity (ROE) of TLRY?
TLRY has a return on equity (ROE) of -6.82%. Its return on capital employed (ROCE) is -2.81%.
Is TLRY a good stock to buy?
This page provides a data-driven analysis of Tilray Brands, Inc. (TLRY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.